title: Chronic intestinal pseudo-obstruction due to buserelin-induced formation of anti-GnRH antibodies.
abstract: OBJECTIVE
  A 30-year-old woman, treated with buserelin, an analogue of gonadotropin-releasing hormone (GnRH) (also called luteinizing hormone-releasing hormone, LH-RH), developed chronic intestinal pseudo-obstruction (CIPO). The sudden onset of this disease in a previously healthy woman perplexed us. CIPO refers to a gastrointestinal disorder that can have a variety of causes, such as drugs, among others. Thus, we wanted to examine whether in this patient the development of CIPO is related to the treatment with buserelin.
  
  
  METHODS
  The patient was examined using esophagogastroduodenoscopy, esophageal, and antroduodenojejunal manometry, gastric emptying tests, and histologic analyses and immunohistochemistry on full-thickness biopsies including staining with anti-GnRH antibody. Plasma samples were examined by the standard serologic analyses and specifically for the occurrence of anti-GnRH antibodies by enzyme-linked immunosorbent assay methods.
  
  
  RESULTS
  CIPO was diagnosed based on symptoms (abdominal pain, vomiting, and constipation), and the results of the clinical examinations, such as signs of esophageal aperistalsis, delayed gastric emptying, and small intestinal bursts. Histologic examination revealed a decreased number of myenteric neurons as well as increased neuronal degeneration and an abnormal immune profile. There was a loss of GnRH-containing neurons. The patient had high plasma titers of anti-GnRH antibodies, which occurred on the occasions of the treatment with buserelin.
  
  
  CONCLUSIONS
  Our findings suggest that the patient has developed CIPO due to buserelin-induced formation of anti-GnRH antibodies destroying GnRH-producing neurons of the myenteric plexus.
authors.affiliation: Department of Clinical Sciences, Gastroenterology Division, Malmö University Hospital, Lund University, Malmö, Sweden.
authors.forename: Bodil
authors.initials: B
authors.lastname: Ohlsson
authors.forename: Béla
authors.initials: B
authors.lastname: Veress
authors.forename: Sabina
authors.initials: S
authors.lastname: Janciauskiene
authors.forename: Agneta
authors.initials: A
authors.lastname: Montgomery
authors.forename: Monica
authors.initials: M
authors.lastname: Haglund
authors.forename: Anders
authors.initials: A
authors.lastname: Wallmark
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D002064:Buserelin / Q000009:adverse effects*; D002908:Chronic Disease; D005260:Female; D005300:Fertility Agents, Female / Q000009:adverse effects*; D007987:Gonadotropin-Releasing Hormone / Q000276:immunology*; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy; D007418:Intestinal Pseudo-Obstruction / Q000139:chemically induced* / Q000276:immunology* / Q000473:pathology; D007422:Intestines / Q000276:immunology / Q000294:innervation / Q000473:pathology; D009197:Myenteric Plexus / Q000276:immunology / Q000473:pathology
chemical_list: D001323:Autoantibodies; D005300:Fertility Agents, Female; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin